Tuebingen

• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Pending
  2025-523510-87-00 5 Obesity
• A Phase 1 Study of AIR-001 in Adults with AATD. Pending
  2025-523558-14-00 1 Alpha-1 Antitrypsin Deficiency
• Study to assess how safe and effective is HRX215 in participants who underwent minor and major liver surgery due to colon carcinoma metastas … Pending
  2025-523630-59-00 9 colon carcinoma metastases
• A clinical trial to learn more about the effects of FWY003 in people with geographic atrophy associated with age-related macular degeneratio … Pending
  2025-523704-77-00 4 Geographic atrophy secondary to age-related macular degeneration
• A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta … Pending
  2025-523869-22-00 5 advanced or metastatic extrapulmonary neuroendocrine carcinoma
• A randomized, open-label, Phase III trial to assess the efficacy and safety of BupiZenge compared to lidocaine for pain associated with oral … Pending
  2025-524386-24-00 5 Head and neck cancer
• A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized s … Pending
  2025-524435-39-00 4 Localized Scleroderma
• Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion (NEXUS) Pending
  2026-525349-65-00 4 Diabetic Retinopathy
• A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease Recruiting
  2025-522001-38-00 4 2026-05-27 Crohn’s Disease
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 11 2026-05-26 Moderate to Severe Plaque Psoriasis
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Pruri … Recruiting
  2025-523404-74-00 4 2026-05-26 Prurigo Nodularis
• Efficacy and safety study of intravenous brincidofovir compared to intravenous cidofovir for the treatment of adenovirus infection in childr … Recruiting
  2025-521903-28-00 5 2026-05-06 Adenovirus viremia
• AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting
  2025-520466-22-00 5 2026-04-29 Advanced Platinum-resistant Epithelial Ovarian Cancer
• A study to learn more about how safe finerenone is, when it is taken for a longer time with standard treatment, in children and young adults … Recruiting
  2024-519830-22-00 5 2026-04-27 Heart failure due to systemic left ventricular systolic dysfunction
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/ … Recruiting
  2025-522484-15-00 5 2026-04-27 ER+/HER2- early breast cancer
• L19IL2 or L19TNF or L19IL2/TNF in patients with basal cell carcinoma (BCC) Recruiting
  2025-523229-16-00 4 2026-04-27 locally advanced basal cell carcinoma patients
• L19IL2/TNF in patients with basal cell carcinoma Recruiting
  2025-523230-77-00 4 2026-04-27 Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable t
• L19IL2/L19TNF in patients with cutaneous squamous cell carcinoma Recruiting
  2025-523231-19-00 4 2026-04-27 Cutaneous Squamous Cell Carcinoma
• A Study of how the Medicine Called "Etrasimod" Works in Children With the gut Disease Called Ulcerative Colitis Recruiting
  2025-523100-77-00 4 2026-04-23 Ulcerative Colitis
• Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Recruiting
  2025-522878-36-00 5 2026-04-20 Chronic Spontaneous Urticaria
• A clinical study of MK-1084 with other treatments for non-small cell lung cancer (MK-3475-01F) Recruiting
  2024-512248-47-00 9 2026-04-15 Non-small Cell Lung Cancer (NSCLC)
• Darovasertib before Surgery or Radiation Therapy to Treat Early-stage Eye Cancer (Uveal Melanoma) Recruiting
  2025-522387-32-00 5 2026-04-10 Uveal Melanoma
• A Phase II Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulve … Recruiting
  2025-523013-28-00 4 2026-04-07 Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 5 2026-04-02 Newly Diagnosed AML with an NPM1 mutation

Showing 25–48 of 591 trials